SOWAHA, a Potential Cancer Suppressor Gene, Influences Metabolic Reprogramming in Multiple Cancer Types

Основні поняття

SOWAHA, a cancer suppressor gene, plays a crucial role in the progression of various carcinomas, particularly through mechanisms involving metabolic reprogramming.

Анотація

This study provides a comprehensive pan-cancer analysis of the tumor suppressor gene SOWAHA. The key findings are:

1. SOWAHA is significantly downregulated in 12 cancer types but upregulated in 14 cancer types. Low expression of SOWAHA is associated with poor prognosis in several epithelial cancers.

2. SOWAHA displays genetic alterations, including mutations and copy number variations, across multiple cancer types. Its expression is correlated with the mutational status of key cancer driver genes like EGFR, PIK3CA, and TP53.

3. DNA methylation of SOWAHA is significantly associated with patient survival in various cancers. Methylation at specific CpG sites can either positively or negatively impact prognosis.

4. SOWAHA expression is correlated with immune cell infiltration, tumor heterogeneity, and stemness in multiple cancer types. It shows both positive and negative associations with the tumor immune microenvironment.

5. Functional enrichment analysis revealed that SOWAHA is significantly involved in metabolic pathways, such as the p53 signaling pathway, PI3K-AKT signaling, and ubiquitin-mediated proteolysis. Knockdown of SOWAHA in colorectal cancer cells enhanced cell proliferation.

6. Two transcription factors, TBX4 and FOXP2, were identified as potential regulators of SOWAHA expression. These transcription factors are known to play roles in cancer progression.

In summary, SOWAHA functions as a tumor suppressor gene, and its dysregulation may contribute to the metabolic reprogramming and development of various carcinomas. SOWAHA could serve as a valuable biomarker for diagnosis, prognosis, and immunotherapy in multiple cancer types.

Статистика

SOWAHA demonstrates early diagnostic potential, with low expression levels linked to poor prognosis in GBMLGG, KIPAN, READ, and other cancers.
SOWAHA is associated with immune cell infiltration, DNA methylation, tumor heterogeneity, and stemness in several epithelial cancers.
Knockdown of SOWAHA in SW620 cells resulted in enhanced cell proliferation and viability.

Цитати

"SOWAHA, identified as a suppressor gene, may also serve as a valuable biomarker for diagnosis, prognosis, and immunotherapy in various carcinomas, particularly colorectal carcinoma."
"Its role in the progression of colorectal cancer is primarily mediated through metabolic reprogramming mechanisms."

Ключові висновки, отримані з

SOWAHA as a Cancer Suppressor Gene Influence Metabolic Reprogramming

by Xiaohong Yi,... о arxiv.org 10-03-2024

https://arxiv.org/pdf/2409.16332.pdf

Глибші Запити

What are the specific molecular mechanisms by which SOWAHA regulates metabolic pathways in cancer cells?

SOWAHA, identified as a cancer suppressor gene, plays a crucial role in regulating metabolic pathways in cancer cells through several molecular mechanisms. The study highlights that SOWAHA is significantly enriched in metabolic-related pathways, including the 'P53 signaling pathway', 'PI3K-AKT signaling pathway', and 'Ubiquitin-Mediated Proteolysis'. These pathways are integral to cellular metabolism, influencing processes such as cell growth, proliferation, and apoptosis.

P53 Signaling Pathway: SOWAHA may modulate the P53 pathway, which is pivotal in regulating the cell cycle and promoting apoptosis in response to cellular stress. By influencing P53 activity, SOWAHA can affect metabolic processes that are crucial for maintaining cellular homeostasis and preventing tumorigenesis.

PI3K-AKT Signaling Pathway: This pathway is known for its role in promoting cell survival and growth. SOWAHA's involvement in this pathway suggests that it may help regulate glucose metabolism and lipid synthesis, which are often dysregulated in cancer cells. By modulating this pathway, SOWAHA could influence the metabolic reprogramming that is characteristic of cancer cells, shifting them towards a more glycolytic phenotype.

Ubiquitin-Mediated Proteolysis: SOWAHA's connection to this pathway indicates its potential role in protein degradation processes that are essential for regulating metabolic enzymes and maintaining metabolic balance. This regulation can impact various metabolic pathways, including those involved in energy production and biosynthesis.

RNA Degradation and Sulfur Metabolism: The involvement of SOWAHA in RNA degradation pathways suggests that it may influence the stability of mRNA transcripts related to metabolic enzymes, thereby affecting their expression levels. Additionally, its role in sulfur metabolism could be linked to the synthesis of key biomolecules, such as amino acids and coenzymes, which are vital for cellular metabolism.

Overall, SOWAHA's regulation of these pathways underscores its potential as a key player in metabolic reprogramming in cancer cells, contributing to tumor progression and highlighting its significance as a therapeutic target.

How do the identified transcription factors, TBX4 and FOXP2, interact with SOWAHA to influence cancer progression?

The transcription factors TBX4 and FOXP2 have been identified as potential regulators of SOWAHA, influencing its expression and, consequently, its role in cancer progression.

TBX4: As a member of the T-box transcription factor family, TBX4 is known to play a significant role in embryonic development and has been implicated in various cancers. The study indicates that TBX4 can bind to the promoter region of SOWAHA, suggesting that it may regulate SOWAHA expression. Dysregulation of TBX4 in cancer could lead to altered SOWAHA levels, impacting its tumor-suppressive functions. The downregulation of TBX4 in SOWAHA knockdown experiments indicates that TBX4 may promote SOWAHA expression under normal conditions, and its loss could contribute to cancer progression by reducing SOWAHA levels.

FOXP2: This transcription factor is crucial for neural development and has been associated with various cancers. The study found that FOXP2 is upregulated in SOWAHA knockdown samples, indicating a potential compensatory mechanism in response to reduced SOWAHA levels. FOXP2's binding to the SOWAHA promoter suggests that it may also influence SOWAHA expression. The misregulation of FOXP2 could lead to altered SOWAHA expression, thereby affecting metabolic pathways and promoting tumorigenesis.

The interaction between SOWAHA and these transcription factors highlights a complex regulatory network where TBX4 and FOXP2 may modulate SOWAHA expression, influencing metabolic reprogramming and cancer progression. This interplay suggests that targeting these transcription factors could provide a novel approach to modulating SOWAHA activity in cancer therapy.

Could SOWAHA be a potential therapeutic target for cancer treatment, and what strategies could be explored to modulate its expression or activity?

SOWAHA presents a promising therapeutic target for cancer treatment due to its role as a cancer suppressor gene and its involvement in metabolic reprogramming. Several strategies could be explored to modulate its expression or activity:

Gene Therapy: Directly delivering SOWAHA or its regulatory elements into cancer cells could restore its expression and function. This approach could be particularly effective in cancers where SOWAHA is downregulated, such as colorectal cancer. Techniques like CRISPR/Cas9 could be employed to enhance SOWAHA expression or correct mutations affecting its function.

Small Molecule Modulators: Developing small molecules that can enhance SOWAHA expression or mimic its activity could provide a pharmacological approach to cancer treatment. These compounds could target the transcription factors TBX4 and FOXP2 to promote SOWAHA expression or directly influence the metabolic pathways regulated by SOWAHA.

Epigenetic Modifiers: Since SOWAHA expression is influenced by DNA methylation, using epigenetic drugs to demethylate the SOWAHA promoter could restore its expression in tumors where it is silenced. Agents like 5-azacytidine, which inhibit DNA methylation, could be explored in this context.

Combination Therapies: Combining SOWAHA modulation with existing therapies, such as immunotherapy or targeted therapies, could enhance treatment efficacy. For instance, restoring SOWAHA function may improve the immune response against tumors by modulating the tumor microenvironment and enhancing immune cell infiltration.

Biomarker Development: Given its role in cancer prognosis, SOWAHA could be developed as a biomarker for patient stratification in clinical settings. Identifying patients with low SOWAHA expression could help tailor more aggressive treatment strategies for those at higher risk of poor outcomes.

In conclusion, targeting SOWAHA through these strategies could provide novel avenues for cancer therapy, particularly in epithelial cancers where its expression is significantly correlated with prognosis and tumor progression. Further research is needed to validate these approaches and explore their clinical applicability.